S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   177.22 (+1.25%)
MSFT   423.25 (-1.09%)
META   516.31 (-1.31%)
GOOGL   159.33 (-0.05%)
AMZN   187.78 (-0.67%)
TSLA   172.63 (-1.13%)
NVDA   894.07 (-1.33%)
AMD   164.35 (-3.61%)
NIO   4.17 (-6.50%)
BABA   72.52 (-3.11%)
T   16.40 (-0.12%)
F   12.75 (-2.22%)
MU   124.19 (-2.60%)
GE   155.21 (-1.39%)
CGC   7.97 (-2.21%)
DIS   114.46 (-2.30%)
AMC   2.77 (-1.07%)
PFE   26.14 (-0.76%)
PYPL   65.92 (+0.18%)
XOM   123.22 (+1.17%)
S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   177.22 (+1.25%)
MSFT   423.25 (-1.09%)
META   516.31 (-1.31%)
GOOGL   159.33 (-0.05%)
AMZN   187.78 (-0.67%)
TSLA   172.63 (-1.13%)
NVDA   894.07 (-1.33%)
AMD   164.35 (-3.61%)
NIO   4.17 (-6.50%)
BABA   72.52 (-3.11%)
T   16.40 (-0.12%)
F   12.75 (-2.22%)
MU   124.19 (-2.60%)
GE   155.21 (-1.39%)
CGC   7.97 (-2.21%)
DIS   114.46 (-2.30%)
AMC   2.77 (-1.07%)
PFE   26.14 (-0.76%)
PYPL   65.92 (+0.18%)
XOM   123.22 (+1.17%)
S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   177.22 (+1.25%)
MSFT   423.25 (-1.09%)
META   516.31 (-1.31%)
GOOGL   159.33 (-0.05%)
AMZN   187.78 (-0.67%)
TSLA   172.63 (-1.13%)
NVDA   894.07 (-1.33%)
AMD   164.35 (-3.61%)
NIO   4.17 (-6.50%)
BABA   72.52 (-3.11%)
T   16.40 (-0.12%)
F   12.75 (-2.22%)
MU   124.19 (-2.60%)
GE   155.21 (-1.39%)
CGC   7.97 (-2.21%)
DIS   114.46 (-2.30%)
AMC   2.77 (-1.07%)
PFE   26.14 (-0.76%)
PYPL   65.92 (+0.18%)
XOM   123.22 (+1.17%)
S&P 500   5,146.07 (-1.02%)
DOW   38,110.26 (-0.91%)
QQQ   440.77 (-1.03%)
AAPL   177.22 (+1.25%)
MSFT   423.25 (-1.09%)
META   516.31 (-1.31%)
GOOGL   159.33 (-0.05%)
AMZN   187.78 (-0.67%)
TSLA   172.63 (-1.13%)
NVDA   894.07 (-1.33%)
AMD   164.35 (-3.61%)
NIO   4.17 (-6.50%)
BABA   72.52 (-3.11%)
T   16.40 (-0.12%)
F   12.75 (-2.22%)
MU   124.19 (-2.60%)
GE   155.21 (-1.39%)
CGC   7.97 (-2.21%)
DIS   114.46 (-2.30%)
AMC   2.77 (-1.07%)
PFE   26.14 (-0.76%)
PYPL   65.92 (+0.18%)
XOM   123.22 (+1.17%)
NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

$67.67
-0.05 (-0.07%)
(As of 10:21 AM ET)
Today's Range
$67.61
$67.78
50-Day Range
$67.38
$69.65
52-Week Range
$47.59
$69.68
Volume
81,355 shs
Average Volume
1.32 million shs
Market Capitalization
$3.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.73

Axonics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
4.5% Upside
$70.73 Price Target
Short Interest
Bearish
6.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.71mentions of Axonics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$4.46 M Sold Last Quarter
Proj. Earnings Growth
100.00%
From $0.32 to $0.64 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

697th out of 2,784 stocks

Surgical & Medical Instruments Industry

94th out of 285 stocks

AXNX stock logo

About Axonics Stock (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock Price History

AXNX Stock News Headlines

Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Axonics Responds to ITC Action by Medtronic
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Axonics just downgraded at Morgan Stanley, here's why
Axonics just downgraded at Truist, here's why
Axonics just downgraded at CL King, here's why
Axonics just downgraded at Leerink, here's why
Analyst Scoreboard: 5 Ratings For Axonics
Axonics just downgraded at RBC Capital, here's why
Why Is Axonics (AXNX) Stock Up 20% Today?
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/12/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AXNX
Employees
797
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.73
High Stock Price Target
$75.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+4.4%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-6,090,000.00
Pretax Margin
-2.39%

Debt

Sales & Book Value

Annual Sales
$366.38 million
Cash Flow
$0.13 per share
Book Value
$12.59 per share

Miscellaneous

Free Float
50,059,000
Market Cap
$3.45 billion
Optionable
Optionable
Beta
0.56
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

AXNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price target for 2024?

13 brokers have issued 1-year target prices for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they predict the company's share price to reach $70.73 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2024?

Axonics' stock was trading at $62.23 at the beginning of the year. Since then, AXNX shares have increased by 8.7% and is now trading at $67.67.
View the best growth stocks for 2024 here
.

Are investors shorting Axonics?

Axonics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,440,000 shares, an increase of 17.0% from the March 15th total of 2,940,000 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is currently 2.5 days.
View Axonics' Short Interest
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) issued its quarterly earnings data on Wednesday, February, 28th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.07. The company had revenue of $109.70 million for the quarter, compared to analysts' expectations of $107.33 million. Axonics had a negative trailing twelve-month return on equity of 1.00% and a negative net margin of 1.66%. Axonics's revenue was up 27.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 earnings per share.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Axonics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Fort Pitt Capital Group LLC (0.01%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXNX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners